List of Figures
Figure 1: Alzheimer’s Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987–2014 8
Figure 2: Alzheimer’s Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 9
Figure 3: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Market by Molecular Target, 2017 24
Figure 4: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Associated Indications Market by Molecular Target, 2017 25
Figure 5: Alzheimer’s Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017 30
Figure 6: Alzheimer’s Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017 31
Figure 7: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Stage of Development, 2017 32
Figure 8: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecule Type, 2017 33
Figure 9: Alzheimer’s Disease, Global, Pipeline by Molecular Target, 2017 34
Figure 10: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecular Target, 2017 36
Figure 11: Alzheimer’s Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 37
Figure 12: Alzheimer’s-Disease-Associated Indications, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 37
Figure 13: Alzheimer’s Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 39
Figure 14: Alzheimer’s Disease, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017 40
Figure 15: Alzheimer’s-Disease-Associated Indications, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 42
Figure 16: Alzheimer’s-Disease-Associated Indications, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017 43
Figure 17: Alzheimer’s Disease, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017 45
Figure 18: Alzheimer’s-Disease-Associated Indications, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017 47
Figure 19: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 1) 48
Figure 20: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 2) 49
Figure 21: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 3) 50
Figure 22: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 4) 51
Figure 23: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 5) 52
Figure 24: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 6) 53
Figure 25: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 7) 54
Figure 26: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 8) 55
Figure 27: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 8) 56
Figure 28: Alzheimer’s Disease and Associated Indications, Global, List of All Pipeline Programs, 2017 (part 10) 57
Figure 29: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Alzheimer’s Disease Products, 2017 60
Figure 30: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Anxiety Products, 2017 61
Figure 31: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Depression Products, 2017 62
Figure 32: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Psychosis Products, 2017 62
Figure 33: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Insomnia Products, 2017 63
Figure 34: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2014 80
Figure 35: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006–2014 81
Figure 36: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Region, Value and Year, 2006–2017 82
Figure 37: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Indication and Deal Value, 2006–2017 83
Figure 38: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2017 84
Figure 39: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006–2017 84
Figure 40: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006–2017 85
Figure 41: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals Exceeding $100m in Value, 2006–2017 86
Figure 42: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Region, Value and Year, 2006–2017 87
Figure 43: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Indication and Deal Value, 2006–2017 88
Figure 44: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 88
Figure 45: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006–2017 89
Figure 46: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecular Target, 2006–2017 89
Figure 47: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals Exceeding $100m in Value, 2006–2017 90